SI-BONE Achieves 510(k) Clearance and FDA Breakthrough Device Designation

Tuesday, 20 August 2024, 14:24

SI-BONE (SIBN) has successfully received 510(k) clearance for its iFuse TORQ TNT Implant System. This approval signifies a major advancement in treating pelvic fragility fractures, with a notable achievement being the FDA's Breakthrough Device Designation.
LivaRava_Finance_Default_1.png
SI-BONE Achieves 510(k) Clearance and FDA Breakthrough Device Designation

Significant Milestone for SI-BONE

SI-BONE (SIBN) celebrated a monumental achievement by obtaining 510(k) clearance for its innovative iFuse TORQ TNT Implant System. This new device is set to revolutionize the treatment for pelvic fragility fractures, providing enhanced recovery pathways for affected patients.

FDA Breakthrough Device Designation

In addition to the clearance, the device was also awarded FDA Breakthrough Device Designation, highlighting its importance in addressing a significant health challenge. This designation indicates a higher priority for FDA review and advancements in patient care.

Implications for the Medical Field

The iFuse TORQ TNT Implant System not only offers a solution for current treatment challenges but also showcases SI-BONE's commitment to pioneering advanced medical devices. As healthcare professionals seek effective solutions, this system could represent a pivotal change in managing pelvic fractures.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe